36 results about "Antigen Processing Cell" patented technology

Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled using accurate mass, high-resolution liquid chromatography-mass spectrometry (LC-MS / MS). A resource dataset containing thousands of peptides bound to 28 distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.

An attenuated herpes virus capable of efficiently infecting a dendritic cell without preventing antigen processing occurring within the infected cell. The attenuated herpes virus and dentrictic cells infected with the virus are useful in immunotherapeutic methods of treating disease.

By adding the novel developed modular antigen transporter molecules (MAT molecules) and other instruments related thereto, the immune system of an individual can be effectively modulated in a targeted manner. The MAT molecules contain a translocation module which transports the MAT molecule inside the cell, an active intracellular targeting molecule resulting in intracellular transport of the MAT molecule to the organelles of the cell which are responsible for antigen processing and an antigen module which determines the specificity of the immune response modulated by the MAT molecule. Optionally, other modules such as tag modules or spacer modules can be contained in the MAT molecule. The invention comprises the inventive MAT molecules, antibodies which are produced using said MAT molecules and therapeutic agents and diagnostic reagents which are produced with MAT molecules. The invention also comprises applications containing said MAT molecules, antibodies, therapeutic agents and diagnostic reagents.

The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

The invention discloses a genetic engineering subunit oral vaccine strain for preventing porcine epidemic diarrhea as well as a construction method and an application thereof. Autochthonous lactic acid bacteria strains which are separated from intestinal tract of pigs are used as transferring active carriers of vaccine antigens, PEDV S protein neutralizing antigen core epitope domain COE is selected as an immunogen, and at the same time transport speed of the vaccine antigen is effectively improved, immune response time of bodies is shortened, an antigen transporting cell M cell targeting peptide Col and dendritic cell targeting peptide DCpep for antigen processing and presentation is introduced, a constitutive expression carrier is used for constructing a recombined lactic acid bacteria preparation for expressing the PEDV S protein neutralizing antigen core epitope domain COE and a M cell targeting peptide Col and a dendritic cell targeting peptide DCpep, so that the vaccine antigen secretes along with breeding of genetic engineering bacterial strains, and disadvantages of induction type recombined lactic acid bacteria are avoided. An effective technical means is provided for developing the genetic engineering subunit oral vaccine strain for preventing porcine epidemic diarrhea is provided.

An attenuated herpes virus capable of efficiently infecting a dendritic cell without preventing antigen processing occurring within the infected cell. The attenuated herpes virus and dendritic cells infected with the virus are useful immunotherapeutic methods of treating disease.

By adding the novel developed modular antigen transporter molecules (MAT molecules) and other instruments related thereto, the immune system of an individual can be effectively modulated in a targetedmanner. The MAT molecules contain a translocation module which transports the MAT molecule inside the cell, an active intracellular targeting molecule resulting in intracellular transport of the MATmolecule to the organelles of the cell which are responsible for antigen processing and an antigen module which determines the specificity of the immune response modulated by the MAT molecule. Optionally, other modules such as tag modules or spacer modules can be contained in the MAT molecule. The invention comprises the inventive MAT molecules, antibodies which are produced using said MAT molecules and therapeutic agents and diagnostic reagents which are produced with MAT molecules. The invention also comprises applications containing said MAT molecules, antibodies, therapeutic agents and diagnostic reagents.

The invention relates to a medicine as well as a preparation method and application thereof and in particular relates to a medicine with an antigen processing improving function as well as a preparation method and application thereof. The medicine is prepared from a cell autophagy induction molecule, a tumor antigen molecule and a carrier, wherein the autophagy induction molecule and the tumor antigen molecule are connected onto the carrier. According to the medicine, the cell autophagy induction molecule and the tumor antigen molecule are connected onto the same carrier and have the synergistic interaction effect; compared with the effect of a manner of independently connecting the molecules with the carrier and entering cells respectively, the effect of the two molecules is remarkably enhanced; autophagy is effectively induced so that antigen presentation is enhanced; finally, the aim of improving the effect of treating tumors is realized; moreover, autophagy is enhanced by the medicine so that the antigen presentation is improved and the medicine provides a new thought for development of tumor immunotherapy.

The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.

The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.

Belonging to the tumor therapy protein related technical field, the invention specifically relates to a dendritic cell (DC) targeted affinity peptide TY peptide and application thereof. The TY peptideis 12 peptide, and the specific amino acid sequence is TITHFQFGPTVY. Based on the TY peptide, the invention further designs a novel nano-transportation system capable of targeting DC on the basis ofMSN, and loads the model antigen OVA and immunoadjuvant CpG to prepare the nano-carrier MSN(mesoporous silica nanoparticles)-TY / OVA / CpG successfully. Experiments indicate that: the MSN-TY / OVA / CpG canbe effectively ingested by immature DC, thus improving the efficiency of antigen ingestion by DC, promoting the maturation of DC and effectively activating DC, also effectively promoting antigen processing and presentation, stimulating secretion of cytokines, and further triggering antigen-specific CTL immunoreaction and anti-tumor immunoreaction.

The invention relates to a fusion gene useful as a therapeutic and prophylactic vaccine against cancer. The fusion gene contains a DNA encoding ubiquitin gene fused to a second DNA encoding growth factor receptors or fragment thereof, over expressed in various types of cancer. In particular, the invention is illustrated by a recombinant fusion gene comprised of mutated ubiquitin gene and modified extra cellular domain of vasoactive intestinal peptide / pituitary adenylate cyclase activating polypeptide receptor-1 (VPAC1). Immunization with the vaccine will break the self-tolerance for the tumor antigen through effective antigen processing and presentation, leading to retardation / regression of tumor growth.

The invention discloses a single-domain antibody capable of recognizing HLA-A2 / RMFPNAPYL and CDR1, CDR2, and CDR3 sequences having a specific recognition effect. A fusion protein is characterized by being prepared by abovementioned amino acid sequences and at least one polypeptide having a recognition function. A multi-specific or multifunctional molecule comprises the single-domain antibody. A nucleic acid molecule encodes the polypeptide molecule. A carrier comprises the nucleic acid sequence. The nucleotide sequence or at least part of sequence of a protein expressed by the nucleic acid molecule can be expressed by a proper expression system so as to obtain a corresponding protein or polypeptide. A host cell comprises a nucleic acid sequence that expresses the abovementioned protein. The single-domain antibody can recognize an artificially synthesized HLA-A2 / RMFPNAPYL compound, can be combined with a HLA-A2 / RMFPNAPYL compound that is expressed on the surface of tumor cells and is prepared from natural antigen, and can be used to develop a product for treating related tumors.

An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an effective amount of an inhibitor of ERAAP activity; confirming a resultant inhibition of said ERAAP activity and confirming a resultant immune response modulation in the patient. A variety of selective inhibitors are shown to be effective, including amino thiols, such as leucine thiol, ERAAP-specific antibody complementarity-determining region, and an ERAAP-specific siRNA.

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognized by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises a portion of the region 40-60 of myelin oligodendrocyte glycoprotein (MOG). In particular there is provided an apitope which is selected from the following myelin oligodendrocyte glycoprotein peptides: MOG 41-55, 43-57, 44-58 and 45-59. There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and / or prevent a disease using such a peptide.

The present invention provides peptides partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides peptides comprising the sequence DNIMVTFRNQASRPY or PRCLTRYYSSFVNME with modifications at the N- and C-termini. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

Tapasin (Tpn) is a member of the MHC Class I loading complex and functions to bridge the TAP peptide transporter to MHC Class I molecules. Metastatic human carcinomas express low levels of the antigen processing components (APCs) tapasin and TAP, and display few functional surface MHC Class I molecules. As a result, carcinomas are often unrecognizable by effector cytolytic T cells (CTLs). Tpn alone can enhance survival and immunity of mammals against tumors, but additionally, Tpn and TAP can be used together as components of immunotherapeutic vaccine protocols to eradicate tumors.

A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and / or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or, preferably, as an immunogenicity-enhancing adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.

The present invention provides a tandem expression of common antigenic epitopes of feline calicivirus GI and GII strain groups and the establishment of an indirect ELISA method. Using a prokaryotic expression vector, multiple B cell antigens of feline calicivirus VP1 protein were expressed in tandem. The expressed recombinant protein was purified and used as a coating antigen for the detection of feline calicivirus antibodies. A parallel comparison with the method of encapsulating whole virus showed that the value of detecting negative and positive sera was highly consistent. The antigen processing of the invention is convenient, the test time is shortened, and the operation steps are simpler. The invention establishes an indirect ELISA method for detecting the antibody level of feline calicivirus in cat serum, has the characteristics of good repeatability and high specificity, and can be used for feline calicivirus serological investigation. Therefore, the feline calicivirus indirect ELISA detection kit based on the tandem expression of the VP1 protein B cell antigen provided by the present invention is very suitable for the detection of large clinical samples, and is suitable for large-scale promotion.

The present invention provides methods for antigen and / or bioactive molecule delivery to antigen presenting cells utilizing ASC specks as vehicles; 1) the ASC speck composition is made of ASC protein(s) and the antigen and / or bioactive molecule(s) purified from cells as a compact micro-spherical structure; 2) purified micro-spherical ASC speck delivery vehicles are stable at 37° C. for more than 30 days; and 3) antigen and / or bioactive molecules carried by ASC specks can be efficiently phagocytosed by antigen presenting cells and their degradation in the lysosome allows antigen processing and presentation.

There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises all or a portion of the following proteolipid protein (PLP) peptides: PLP 36-61: HE ALTGTEKLIET YF SKN YQD YEYLI (SEQ ID NO. 1) PLP 179-206: TWTTCQSIAFPSKTSASIGSLCA DARMY (SEQ ID NO. 2) PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3). There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and / or prevent a disease using such a peptide.

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and / or acquired haemophilia.

The invention relates to a medicine as well as a preparation method and application thereof and in particular relates to a medicine with an antigen processing improving function as well as a preparation method and application thereof. The medicine is prepared from a cell autophagy induction molecule, a tumor antigen molecule and a carrier, wherein the autophagy induction molecule and the tumor antigen molecule are connected onto the carrier. According to the medicine, the cell autophagy induction molecule and the tumor antigen molecule are connected onto the same carrier and have the synergistic interaction effect; compared with the effect of a manner of independently connecting the molecules with the carrier and entering cells respectively, the effect of the two molecules is remarkably enhanced; autophagy is effectively induced so that antigen presentation is enhanced; finally, the aim of improving the effect of treating tumors is realized; moreover, autophagy is enhanced by the medicine so that the antigen presentation is improved and the medicine provides a new thought for development of tumor immunotherapy.

A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and / or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition may be used alone or, preferably, as an immunogenicity-enhancing adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.